关于 BET 抑制剂在前列腺增生症治疗中的潜在应用的问与答
发布日期 3 月 15, 20173/15/17
On February 13, Canadian biotech, Reserverlogix announced that facioscapulohumeral muscular dystrophy (FSHD) is one of two new indications it is pursuing involving its lead drug, apabetalone (RVX-208) which inhibits bromodomain […]